A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

Mostrar otras versiones (1)

Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here we report on a fluorescence-bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Muruato, Antonio E., Fontes-Garfias, Camila R., Ren, Ping, Garcia-Blanco, Mariano A., Menachery, Vineet D., Xie, Xuping, Shi, Pei-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263515/
https://www.ncbi.nlm.nih.gov/pubmed/32511386
http://dx.doi.org/10.1101/2020.05.21.109546
Descripción
Sumario:Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. Our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.

Ejemplares similares